AC Immune SA (NASDAQ:ACIU) – Research analysts at Svb Leerink boosted their Q4 2019 earnings estimates for AC Immune in a research report issued to clients and investors on Wednesday, November 13th. Svb Leerink analyst M. Goodman now anticipates that the company will earn ($0.25) per share for the quarter, up from their previous estimate of ($0.26). Svb Leerink also issued estimates for AC Immune’s FY2022 earnings at $3.40 EPS and FY2023 earnings at $8.75 EPS.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings results on Wednesday, November 13th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.08. The business had revenue of $33.90 million during the quarter, compared to analysts’ expectations of $31.50 million. AC Immune had a return on equity of 19.18% and a net margin of 45.19%.

Several other equities research analysts have also issued reports on the company. Zacks Investment Research lowered AC Immune from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. ValuEngine lowered AC Immune from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. Finally, BidaskClub raised AC Immune from a “sell” rating to a “hold” rating in a research note on Tuesday, October 29th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company. AC Immune currently has an average rating of “Hold” and a consensus target price of $9.83.

NASDAQ ACIU opened at $6.96 on Monday. The stock has a market capitalization of $464.15 million, a PE ratio of -8.49 and a beta of 0.09. The business has a 50 day simple moving average of $5.25 and a two-hundred day simple moving average of $5.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 22.08 and a quick ratio of 21.90. AC Immune has a 1-year low of $3.25 and a 1-year high of $12.50.

Several large investors have recently bought and sold shares of ACIU. Cubist Systematic Strategies LLC bought a new stake in shares of AC Immune in the 2nd quarter valued at approximately $58,000. Tower Research Capital LLC TRC bought a new stake in shares of AC Immune in the 3rd quarter valued at approximately $62,000. Appleton Partners Inc. MA bought a new stake in shares of AC Immune in the 2nd quarter valued at approximately $85,000. JPMorgan Chase & Co. lifted its stake in shares of AC Immune by 20.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 18,162 shares of the company’s stock valued at $99,000 after purchasing an additional 3,113 shares during the last quarter. Finally, Athanor Capital LP bought a new stake in shares of AC Immune in the 2nd quarter valued at approximately $234,000. 26.67% of the stock is owned by institutional investors and hedge funds.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Further Reading: How Do I Invest in Dividend Stocks

Earnings History and Estimates for AC Immune (NASDAQ:ACIU)

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.